Carole Miller is an Oncology physician affiliated with Saint Agnes Hospital. OpenAlex indexes 145 publications with 11,851 citations (h-index 42); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
900 Caton Ave
Baltimore, MD 212295201
Telephone
667-234-2910Registry record last updated 25 Apr 2018.
Clinical trials
- Cyclophosphamide Plus Topotecan in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Caris MPI, Inc.Program year20251 payment
- Incyte CorporationProgram year20241 payment
- Incyte CorporationProgram year20239 payments$12,628openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
39.6%Kinase inhibitor23.4%Jakafi43%Tasigna18%Sprycel15%Calquence13%Imatinib Mesylate10%Part D<11 patientsAntimetabolite8.4%Hydroxyurea100%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
23.2%Proton pump inhibitor8.6%Pantoprazole Sodium100%Part D≥12 patientsCorticosteroid6.2%Prednisone100%Part D≥12 patients+ 2 more classes in this area
Anti-infectives
17.8%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor9.6%Valacyclovir100%Part D≥15 patientsShort-acting sulfonamides8.2%Sulfamethoxazole-Trimethoprim100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2001–2002 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Targeted FGFR Blockade for the Treatment of Tumor-Induced Osteomalacia
New England Journal of Medicine
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Zatina, MD
Saint Agnes Hospital
Marian Lamonte, MD, MSN
Saint Agnes Hospital
Ronald Gillilan, MD
Saint Agnes Hospital
Omar Karim, MD
Saint Agnes Hospital
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”